These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31158314)

  • 1. Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.
    Pagano G; Niccolini F; Wilson H; Yousaf T; Khan NL; Martino D; Plisson C; Gunn RN; Rabiner EA; Piccini P; Foltynie T; Politis M
    Mov Disord; 2019 Oct; 34(10):1505-1515. PubMed ID: 31158314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.
    Niccolini F; Foltynie T; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Kapur S; Rabiner EA; Gunn RN; Piccini P; Politis M
    Brain; 2015 Oct; 138(Pt 10):3003-15. PubMed ID: 26210536
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Li W; Lao-Kaim NP; Roussakis AA; Martín-Bastida A; Valle-Guzman N; Paul G; Loane C; Widner H; Politis M; Foltynie T; Barker RA; Piccini P
    Mov Disord; 2018 Jan; 33(1):117-127. PubMed ID: 29082547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal DAT changes measured with [
    Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
    Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
    Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
    J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[β-(11)C]DOPA and [(18)F]FE-PE2I in humans.
    Suzuki M; Ito H; Kodaka F; Takano H; Kimura Y; Fujiwara H; Sasaki T; Takahata K; Nogami T; Nagashima T; Nengaki N; Kawamura K; Zhang MR; Varrone A; Halldin C; Okubo Y; Suhara T
    Nucl Med Commun; 2014 Mar; 35(3):231-7. PubMed ID: 24468851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
    Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL
    J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification and discriminative power of
    Delva A; Van Weehaeghe D; van Aalst J; Ceccarini J; Koole M; Baete K; Nuyts J; Vandenberghe W; Van Laere K
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1913-1926. PubMed ID: 31776633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
    Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
    Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease.
    Delva A; Van Laere K; Vandenberghe W
    Mov Disord; 2022 Sep; 37(9):1883-1892. PubMed ID: 35819412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplified quantification of [
    Brumberg J; Kerstens V; Cselényi Z; Svenningsson P; Sundgren M; Fazio P; Varrone A
    J Cereb Blood Flow Metab; 2021 Jun; 41(6):1291-1300. PubMed ID: 32955955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107.
    Marques TR; Natesan S; Niccolini F; Politis M; Gunn RN; Searle GE; Howes O; Rabiner EA; Kapur S
    Am J Psychiatry; 2016 Jul; 173(7):714-21. PubMed ID: 26892941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease.
    Eshuis SA; Maguire RP; Leenders KL; Jonkman S; Jager PL
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):200-9. PubMed ID: 16228235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related decline in dopamine transporter in human brain using PET with a new radioligand [¹⁸F]FE-PE2I.
    Shingai Y; Tateno A; Arakawa R; Sakayori T; Kim W; Suzuki H; Okubo Y
    Ann Nucl Med; 2014 Apr; 28(3):220-6. PubMed ID: 24385293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
    Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
    J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [
    Honhar P; Ebrahimian Sadabad F; Tinaz S; Gallezot JD; Dias M; Naganawa M; Yang Y; Henry S; Hillmer AT; Gao H; Najafzadeh S; Comley R; Nabulsi N; Huang Y; Finnema SJ; Carson RE; Matuskey D
    Brain Commun; 2024; 6(5):fcae345. PubMed ID: 39429243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
    Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
    Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
    Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.